| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Sufentanil. | Experimental, Illicit |
| 3,4-Methylenedioxyamphetamine | 3,4-Methylenedioxyamphetamine may increase the analgesic activities of Sufentanil. | Experimental, Illicit |
| 3,4-Methylenedioxymethamphetamine | 3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Sufentanil. | Experimental, Illicit |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Sufentanil. | Experimental, Illicit |
| 7-Nitroindazole | The risk or severity of adverse effects can be increased when Sufentanil is combined with 7-Nitroindazole. | Experimental |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | Sufentanil may increase the serotonergic activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE. | Experimental |
| Acebutolol | Sufentanil may increase the bradycardic activities of Acebutolol. | Approved |
| Acepromazine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Acepromazine. | Approved, Vet Approved |
| Aceprometazine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Aceprometazine. | Approved |
| Acetazolamide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Acetazolamide. | Approved, Vet Approved |
| Aclidinium | The risk or severity of adverse effects can be increased when Aclidinium is combined with Sufentanil. | Approved |
| Adipiplon | The risk or severity of adverse effects can be increased when Sufentanil is combined with adipiplon. | Investigational |
| Agomelatine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Agomelatine. | Approved, Investigational |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sufentanil. | Approved |
| Alfaxalone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Alfaxalone. | Vet Approved |
| Alfentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Alfentanil. | Approved, Illicit |
| Alimemazine | Alimemazine may increase the hypotensive activities of Sufentanil. | Approved, Vet Approved |
| Aliskiren | The risk or severity of adverse effects can be increased when Aliskiren is combined with Sufentanil. | Approved, Investigational |
| Allopregnanolone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Sage 547. | Investigational |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Alphacetylmethadol. | Experimental, Illicit |
| Alprazolam | The risk or severity of adverse effects can be increased when Alprazolam is combined with Sufentanil. | Approved, Illicit, Investigational |
| Alprenolol | Sufentanil may increase the bradycardic activities of Alprenolol. | Approved, Withdrawn |
| Alvimopan | The risk or severity of adverse effects can be increased when Sufentanil is combined with Alvimopan. | Approved |
| Amifostine | The risk or severity of adverse effects can be increased when Amifostine is combined with Sufentanil. | Approved, Investigational |
| Amiloride | The risk or severity of adverse effects can be increased when Sufentanil is combined with Amiloride. | Approved |
| Amiodarone | The metabolism of Sufentanil can be decreased when combined with Amiodarone. | Approved, Investigational |
| Amisulpride | The risk or severity of adverse effects can be increased when Sufentanil is combined with Amisulpride. | Approved, Investigational |
| Amitriptyline | The risk or severity of adverse effects can be increased when Sufentanil is combined with Amitriptyline. | Approved |
| Amlodipine | The risk or severity of adverse effects can be increased when Amlodipine is combined with Sufentanil. | Approved |
| Ammonium chloride | Ammonium chloride may increase the excretion rate of Sufentanil which could result in a lower serum level and potentially a reduction in efficacy. | Approved, Vet Approved |
| Amobarbital | The risk or severity of adverse effects can be increased when Sufentanil is combined with Amobarbital. | Approved, Illicit |
| Amoxapine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Amoxapine. | Approved |
| Amperozide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Amperozide. | Experimental |
| Amphetamine | Amphetamine may increase the analgesic activities of Sufentanil. | Approved, Illicit |
| Amphotericin B | The risk or severity of adverse effects can be increased when Amphotericin B is combined with Sufentanil. | Approved, Investigational |
| Amyl Nitrite | The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Sufentanil. | Approved |
| Anisotropine Methylbromide | The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Sufentanil. | Approved |
| Apomorphine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Sufentanil. | Approved, Investigational |
| Apraclonidine | The risk or severity of adverse effects can be increased when Apraclonidine is combined with Sufentanil. | Approved |
| Aprepitant | The serum concentration of Sufentanil can be increased when it is combined with Aprepitant. | Approved, Investigational |
| Aripiprazole | Aripiprazole may increase the hypotensive activities of Sufentanil. | Approved, Investigational |
| Arotinolol | The risk or severity of adverse effects can be increased when Arotinolol is combined with Sufentanil. | Approved |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sufentanil. | Approved, Investigational |
| Articaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Articaine. | Approved |
| Asenapine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Asenapine. | Approved |
| Atazanavir | The metabolism of Sufentanil can be decreased when combined with Atazanavir. | Approved, Investigational |
| Atenolol | Atenolol may increase the bradycardic activities of Sufentanil. | Approved |
| Atomoxetine | The metabolism of Sufentanil can be decreased when combined with Atomoxetine. | Approved |
| Atracurium besylate | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sufentanil. | Approved |
| Atropine | The risk or severity of adverse effects can be increased when Atropine is combined with Sufentanil. | Approved, Vet Approved |
| Azaperone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Azaperone. | Vet Approved |
| Azelastine | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine. | Approved |
| Azelastine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Azelastine. | Approved |
| Azilsartan medoxomil | The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sufentanil. | Approved |
| Azosemide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Azosemide. | Investigational |
| Baclofen | The risk or severity of adverse effects can be increased when Sufentanil is combined with Baclofen. | Approved |
| Barbexaclone | Barbexaclone may increase the hypotensive activities of Sufentanil. | Experimental |
| Barbital | The risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital. | Illicit |
| Barnidipine | The risk or severity of adverse effects can be increased when Barnidipine is combined with Sufentanil. | Approved |
| Befunolol | Sufentanil may increase the bradycardic activities of Befunolol. | Experimental |
| Benactyzine | The risk or severity of adverse effects can be increased when Benactyzine is combined with Sufentanil. | Withdrawn |
| Benazepril | The risk or severity of adverse effects can be increased when Benazepril is combined with Sufentanil. | Approved, Investigational |
| Bendroflumethiazide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Bendroflumethiazide. | Approved |
| Benmoxin | Sufentanil may increase the serotonergic activities of Benmoxin. | Withdrawn |
| Benperidol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Benperidol. | Investigational |
| Benzatropine | The risk or severity of adverse effects can be increased when Benzatropine is combined with Sufentanil. | Approved |
| Benzocaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Benzocaine. | Approved |
| Benzphetamine | Benzphetamine may increase the analgesic activities of Sufentanil. | Approved, Illicit |
| Benzyl alcohol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Benzyl alcohol. | Approved |
| Bepridil | The risk or severity of adverse effects can be increased when Bepridil is combined with Sufentanil. | Approved, Withdrawn |
| Beractant | Sufentanil may increase the bradycardic activities of Beractant. | Approved |
| Betaxolol | Betaxolol may increase the bradycardic activities of Sufentanil. | Approved |
| Bevantolol | Sufentanil may increase the bradycardic activities of Bevantolol. | Approved |
| Bexarotene | The serum concentration of Sufentanil can be decreased when it is combined with Bexarotene. | Approved, Investigational |
| Biperiden | The risk or severity of adverse effects can be increased when Biperiden is combined with Sufentanil. | Approved |
| Bisoprolol | Bisoprolol may increase the bradycardic activities of Sufentanil. | Approved |
| BL-1020 | BL-1020 may increase the hypotensive activities of Sufentanil. | Investigational |
| Boceprevir | The metabolism of Sufentanil can be decreased when combined with Boceprevir. | Withdrawn |
| Bopindolol | Sufentanil may increase the bradycardic activities of Bopindolol. | Approved |
| Bortezomib | The metabolism of Sufentanil can be decreased when combined with Bortezomib. | Approved, Investigational |
| Bosentan | The serum concentration of Sufentanil can be decreased when it is combined with Bosentan. | Approved, Investigational |
| Bretylium | Bretylium may increase the bradycardic activities of Sufentanil. | Approved |
| Brexpiprazole | The risk or severity of adverse effects can be increased when Sufentanil is combined with Brexpiprazole. | Approved |
| Brimonidine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Brimonidine. | Approved |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved |
| Bromazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam. | Approved, Illicit |
| Bromocriptine | The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sufentanil. | Approved, Investigational |
| Brompheniramine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Brompheniramine. | Approved |
| Brotizolam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Brotizolam. | Approved, Withdrawn |
| Bucindolol | Sufentanil may increase the bradycardic activities of Bucindolol. | Investigational |
| Bufuralol | Sufentanil may increase the bradycardic activities of Bufuralol. | Experimental, Investigational |
| Bumetanide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Bumetanide. | Approved |
| Bupivacaine | The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sufentanil. | Approved, Investigational |
| Bupranolol | Sufentanil may increase the bradycardic activities of Bupranolol. | Approved |
| Buprenorphine | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. | Approved, Illicit, Investigational, Vet Approved |
| Buspirone | The risk or severity of adverse effects can be increased when Buspirone is combined with Sufentanil. | Approved, Investigational |
| Butabarbital | The risk or severity of adverse effects can be increased when Butabarbital is combined with Sufentanil. | Approved, Illicit |
| Butacaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Butacaine. | Vet Approved |
| Butalbital | The risk or severity of adverse effects can be increased when Sufentanil is combined with Butalbital. | Approved, Illicit |
| Butamben | The risk or severity of adverse effects can be increased when Sufentanil is combined with Butamben. | Approved |
| Butethal | The risk or severity of adverse effects can be increased when Sufentanil is combined with Butethal. | Approved, Illicit |
| Butorphanol | Butorphanol may decrease the analgesic activities of Sufentanil. | Approved, Illicit, Vet Approved |
| Calfactant | Sufentanil may increase the bradycardic activities of Calfactant. | Approved |
| Canagliflozin | The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sufentanil. | Approved |
| Candesartan | The risk or severity of adverse effects can be increased when Candesartan is combined with Sufentanil. | Approved |
| Canrenoic acid | The risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenoic acid. | Approved, Withdrawn |
| Canrenone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenone. | Investigational |
| Captopril | The risk or severity of adverse effects can be increased when Captopril is combined with Sufentanil. | Approved |
| Carbamazepine | The metabolism of Sufentanil can be increased when combined with Carbamazepine. | Approved, Investigational |
| Carbetocin | The risk or severity of adverse effects can be increased when Carbetocin is combined with Sufentanil. | Approved |
| Carbinoxamine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Carbinoxamine. | Approved |
| Carfentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Carfentanil. | Illicit, Vet Approved |
| Carisoprodol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Carisoprodol. | Approved |
| Caroxazone | Sufentanil may increase the serotonergic activities of Caroxazone. | Withdrawn |
| Carteolol | Carteolol may increase the bradycardic activities of Sufentanil. | Approved |
| Carvedilol | Sufentanil may increase the bradycardic activities of Carvedilol. | Approved, Investigational |
| Celiprolol | Sufentanil may increase the bradycardic activities of Celiprolol. | Approved, Investigational |
| Ceritinib | Sufentanil may increase the bradycardic activities of Ceritinib. | Approved |
| Cetirizine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Cetirizine. | Approved |
| Chloral hydrate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Chloral hydrate. | Approved, Illicit, Vet Approved |
| Chlordiazepoxide | The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sufentanil. | Approved, Illicit |
| Chlormezanone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlormezanone. | Approved, Withdrawn |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Chloroprocaine. | Approved |
| Chlorothiazide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide. | Approved, Vet Approved |
| Chlorphenamine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorphenamine. | Approved |
| Chlorphenoxamine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Sufentanil. | Withdrawn |
| Chlorphentermine | Chlorphentermine may increase the analgesic activities of Sufentanil. | Illicit, Withdrawn |
| Chlorpromazine | The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sufentanil. | Approved, Vet Approved |
| Chlorprothixene | The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorprothixene. | Approved, Withdrawn |
| Chlorthalidone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorthalidone. | Approved |
| Chlorzoxazone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorzoxazone. | Approved |
| Cicletanine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Cicletanine. | Investigational |
| Cilazapril | The risk or severity of adverse effects can be increased when Cilazapril is combined with Sufentanil. | Approved |
| Cilnidipine | The risk or severity of adverse effects can be increased when Cilnidipine is combined with Sufentanil. | Approved |
| Cinchocaine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Sufentanil. | Approved, Vet Approved |
| Citalopram | Sufentanil may increase the serotonergic activities of Citalopram. | Approved |
| Clarithromycin | The metabolism of Sufentanil can be decreased when combined with Clarithromycin. | Approved |
| Clemastine | The metabolism of Sufentanil can be decreased when combined with Clemastine. | Approved |
| Clevidipine | The risk or severity of adverse effects can be increased when Clevidipine is combined with Sufentanil. | Approved |
| Clidinium | The risk or severity of adverse effects can be increased when Sufentanil is combined with Clidinium. | Approved |
| Clobazam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Clobazam. | Approved, Illicit |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Sufentanil. | Approved, Investigational |
| clomethiazole | The risk or severity of adverse effects can be increased when Sufentanil is combined with clomethiazole. | Investigational |
| Clomipramine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Clomipramine. | Approved, Vet Approved |
| Clonazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Clonazepam. | Approved, Illicit |
| Clonidine | Clonidine may increase the bradycardic activities of Sufentanil. | Approved |
| Clorazepate | The risk or severity of adverse effects can be increased when Clorazepate is combined with Sufentanil. | Approved, Illicit |
| Clotrimazole | The metabolism of Sufentanil can be decreased when combined with Clotrimazole. | Approved, Vet Approved |
| Clozapine | The risk or severity of adverse effects can be increased when Clozapine is combined with Sufentanil. | Approved |
| Cobicistat | The metabolism of Sufentanil can be decreased when combined with Cobicistat. | Approved |
| Cocaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Cocaine. | Approved, Illicit |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Sufentanil. | Approved, Illicit |
| Conivaptan | The serum concentration of Sufentanil can be increased when it is combined with Conivaptan. | Approved, Investigational |
| Crizotinib | The metabolism of Sufentanil can be decreased when combined with Crizotinib. | Approved |
| Cyclizine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclizine. | Approved |
| Cyclobenzaprine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine. | Approved |
| Cyclopentolate | The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Sufentanil. | Approved |
| Cyclosporine | The metabolism of Sufentanil can be decreased when combined with Cyclosporine. | Approved, Investigational, Vet Approved |
| Cyclothiazide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclothiazide. | Approved |
| Cyproheptadine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyproheptadine. | Approved |
| Dabrafenib | The serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib. | Approved |
| Dantrolene | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene. | Approved |
| Dapagliflozin | The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sufentanil. | Approved |
| Dapiprazole | The risk or severity of adverse effects can be increased when Dapiprazole is combined with Sufentanil. | Approved |
| Dapoxetine | Sufentanil may increase the serotonergic activities of Dapoxetine. | Investigational |
| Darifenacin | The risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil. | Approved, Investigational |
| Darunavir | The metabolism of Sufentanil can be decreased when combined with Darunavir. | Approved |
| Dasatinib | The serum concentration of Sufentanil can be increased when it is combined with Dasatinib. | Approved, Investigational |
| Deferasirox | The serum concentration of Sufentanil can be decreased when it is combined with Deferasirox. | Approved, Investigational |
| Delavirdine | The metabolism of Sufentanil can be decreased when combined with Delavirdine. | Approved |
| Deramciclane | The risk or severity of adverse effects can be increased when Sufentanil is combined with deramciclane. | Investigational |
| Desflurane | The risk or severity of adverse effects can be increased when Sufentanil is combined with Desflurane. | Approved |
| Desipramine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Desipramine. | Approved |
| Desloratadine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Desloratadine. | Approved, Investigational |
| Desmopressin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin. | Approved |
| Desvenlafaxine | Sufentanil may increase the serotonergic activities of Desvenlafaxine. | Approved |
| Detomidine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Detomidine. | Vet Approved |
| Dexamethasone | The serum concentration of Sufentanil can be decreased when it is combined with Dexamethasone. | Approved, Investigational, Vet Approved |
| Dexbrompheniramine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine. | Approved |
| Dexetimide | The risk or severity of adverse effects can be increased when Dexetimide is combined with Sufentanil. | Withdrawn |
| Dexmedetomidine | Dexmedetomidine may increase the bradycardic activities of Sufentanil. | Approved, Vet Approved |
| Dextroamphetamine | Dextroamphetamine may increase the analgesic activities of Sufentanil. | Approved, Illicit |
| Dextromoramide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dextromoramide. | Experimental, Illicit |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sufentanil. | Approved, Illicit, Withdrawn |
| Dezocine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dezocine. | Approved |
| Diazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Diazepam. | Approved, Illicit, Vet Approved |
| Diclofenamide | The risk or severity of adverse effects can be increased when Diclofenamide is combined with Sufentanil. | Approved |
| Dicyclomine | The risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil. | Approved |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Sufentanil. | Approved, Illicit |
| Difenoxin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Difenoxin. | Approved, Illicit |
| Digoxin | Digoxin may increase the bradycardic activities of Sufentanil. | Approved |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydrocodeine. | Approved, Illicit |
| Dihydroergotamine | The metabolism of Sufentanil can be decreased when combined with Dihydroergotamine. | Approved |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydroetorphine. | Experimental, Illicit |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydromorphine. | Experimental, Illicit |
| Diltiazem | The metabolism of Sufentanil can be decreased when combined with Diltiazem. | Approved |
| Dimenhydrinate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dimenhydrinate. | Approved |
| Dinutuximab | The risk or severity of adverse effects can be increased when Dinutuximab is combined with Sufentanil. | Approved |
| Diphenhydramine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenhydramine. | Approved |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenoxylate. | Approved, Illicit |
| Dipyridamole | The risk or severity of adverse effects can be increased when Dipyridamole is combined with Sufentanil. | Approved |
| Donepezil | Sufentanil may increase the bradycardic activities of Donepezil. | Approved |
| Doramectin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Doramectin. | Vet Approved |
| Doxazosin | The risk or severity of adverse effects can be increased when Doxazosin is combined with Sufentanil. | Approved |
| Doxepin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Doxepin. | Approved |
| Doxycycline | The metabolism of Sufentanil can be decreased when combined with Doxycycline. | Approved, Investigational, Vet Approved |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved, Vet Approved |
| DPDPE | The risk or severity of adverse effects can be increased when Sufentanil is combined with DPDPE. | Investigational |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved, Illicit |
| Dronedarone | The metabolism of Sufentanil can be decreased when combined with Dronedarone. | Approved |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved, Vet Approved |
| Drospirenone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Drospirenone. | Approved |
| Drotebanol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Drotebanol. | Experimental, Illicit |
| Duloxetine | Sufentanil may increase the orthostatic hypotensive activities of Duloxetine. | Approved |
| Dyclonine | The risk or severity of adverse effects can be increased when Dyclonine is combined with Sufentanil. | Approved |
| Ecgonine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ecgonine. | Experimental, Illicit |
| Ecopipam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ecopipam. | Investigational |
| Efavirenz | The serum concentration of Sufentanil can be decreased when it is combined with Efavirenz. | Approved, Investigational |
| Efonidipine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Efonidipine. | Approved |
| Eltanolone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Pregnanolone. | Investigational |
| Eluxadoline | Sufentanil may increase the constipating activities of Eluxadoline. | Approved |
| Empagliflozin | The risk or severity of adverse effects can be increased when Empagliflozin is combined with Sufentanil. | Approved |
| Enalapril | The risk or severity of adverse effects can be increased when Enalapril is combined with Sufentanil. | Approved, Vet Approved |
| Enalaprilat | The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sufentanil. | Approved |
| Enflurane | The risk or severity of adverse effects can be increased when Enflurane is combined with Sufentanil. | Approved, Vet Approved |
| Entacapone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Entacapone. | Approved, Investigational |
| Enzalutamide | The serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide. | Approved |
| Eplerenone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Eplerenone. | Approved |
| Epoprostenol | The risk or severity of adverse effects can be increased when Epoprostenol is combined with Sufentanil. | Approved |
| Eprosartan | The risk or severity of adverse effects can be increased when Eprosartan is combined with Sufentanil. | Approved |
| Erythromycin | The metabolism of Sufentanil can be decreased when combined with Erythromycin. | Approved, Vet Approved |
| Escitalopram | Sufentanil may increase the serotonergic activities of Escitalopram. | Approved, Investigational |
| Eslicarbazepine acetate | The serum concentration of Sufentanil can be decreased when it is combined with Eslicarbazepine acetate. | Approved |
| Esmolol | Esmolol may increase the bradycardic activities of Sufentanil. | Approved |
| Estazolam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Estazolam. | Approved, Illicit |
| Eszopiclone | The risk or severity of adverse effects can be increased when Eszopiclone is combined with Sufentanil. | Approved |
| Etacrynic acid | The risk or severity of adverse effects can be increased when Sufentanil is combined with Etacrynic acid. | Approved |
| Ethanol | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol. | Approved |
| Ethchlorvynol | The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sufentanil. | Approved, Illicit, Withdrawn |
| Ethopropazine | The risk or severity of adverse effects can be increased when Ethopropazine is combined with Sufentanil. | Approved |
| Ethosuximide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethosuximide. | Approved |
| Ethotoin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethotoin. | Approved |
| Ethoxzolamide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethoxzolamide. | Withdrawn |
| Ethyl carbamate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl carbamate. | Withdrawn |
| Ethyl loflazepate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl loflazepate. | Approved, Illicit |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethylmorphine. | Approved, Illicit |
| Etidocaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Etidocaine. | Approved |
| Etifoxine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Etifoxine. | Withdrawn |
| Etizolam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Etizolam. | Approved |
| Etomidate | The risk or severity of adverse effects can be increased when Etomidate is combined with Sufentanil. | Approved |
| Etoperidone | Sufentanil may increase the serotonergic activities of Etoperidone. | Approved |
| Etorphine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Etorphine. | Illicit, Vet Approved |
| Etravirine | The serum concentration of Sufentanil can be decreased when it is combined with Etravirine. | Approved |
| Ezogabine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ezogabine. | Approved |
| Felbamate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Felbamate. | Approved |
| Felodipine | The risk or severity of adverse effects can be increased when Felodipine is combined with Sufentanil. | Approved, Investigational |
| Fencamfamine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Fencamfamine. | Approved, Illicit, Withdrawn |
| Fenoldopam | The risk or severity of adverse effects can be increased when Fenoldopam is combined with Sufentanil. | Approved |
| Fentanyl | The risk or severity of adverse effects can be increased when Sufentanil is combined with Fentanyl. | Approved, Illicit, Investigational, Vet Approved |
| Fesoterodine | The risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil. | Approved |
| Fexofenadine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Fexofenadine. | Approved |
| Fimasartan | The risk or severity of adverse effects can be increased when Fimasartan is combined with Sufentanil. | Approved |
| Fingolimod | Sufentanil may increase the bradycardic activities of Fingolimod. | Approved, Investigational |
| Flibanserin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Flibanserin. | Approved |
| Fluconazole | The metabolism of Sufentanil can be decreased when combined with Fluconazole. | Approved |
| Fludiazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Fludiazepam. | Approved, Illicit |
| Flunarizine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Flunarizine. | Approved |
| Flunitrazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Flunitrazepam. | Approved, Illicit |
| Fluoxetine | Sufentanil may increase the serotonergic activities of Fluoxetine. | Approved, Vet Approved |
| Flupentixol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Flupentixol. | Approved, Withdrawn |
| Fluphenazine | The risk or severity of adverse effects can be increased when Fluphenazine is combined with Sufentanil. | Approved |
| Flurazepam | The risk or severity of adverse effects can be increased when Flurazepam is combined with Sufentanil. | Approved, Illicit |
| Fluspirilene | The risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene. | Approved |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Fluticasone Propionate. | Approved |
| Fluvoxamine | The metabolism of Sufentanil can be decreased when combined with Fluvoxamine. | Approved, Investigational |
| Fosamprenavir | The metabolism of Sufentanil can be decreased when combined with Fosamprenavir. | Approved |
| Fosaprepitant | The serum concentration of Sufentanil can be increased when it is combined with Fosaprepitant. | Approved |
| Fosinopril | The risk or severity of adverse effects can be increased when Fosinopril is combined with Sufentanil. | Approved |
| Fosphenytoin | The metabolism of Sufentanil can be increased when combined with Fosphenytoin. | Approved |
| Fospropofol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Fospropofol. | Approved, Illicit |
| Furazolidone | Sufentanil may increase the serotonergic activities of Furazolidone. | Approved, Vet Approved |
| Furosemide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Furosemide. | Approved, Vet Approved |
| Fusidic Acid | The serum concentration of Sufentanil can be increased when it is combined with Fusidic Acid. | Approved |
| Gabapentin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin. | Approved, Investigational |
| Gabapentin Enacarbil | The risk or severity of adverse effects can be increased when Sufentanil is combined with gabapentin enacarbil. | Approved |
| Galantamine | Galantamine may increase the bradycardic activities of Sufentanil. | Approved |
| Gallamine Triethiodide | The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Sufentanil. | Approved |
| Gamma Hydroxybutyric Acid | The risk or severity of adverse effects can be increased when Sufentanil is combined with Gamma Hydroxybutyric Acid. | Approved, Illicit |
| Gepirone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Gepirone. | Investigational |
| Glutethimide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Glutethimide. | Approved, Illicit |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Sufentanil. | Approved, Investigational, Vet Approved |
| Guanfacine | Sufentanil may increase the bradycardic activities of Guanfacine. | Approved, Investigational |
| Halazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Halazepam. | Approved, Illicit, Withdrawn |
| Haloperidol | The risk or severity of adverse effects can be increased when Haloperidol is combined with Sufentanil. | Approved |
| Halothane | The risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane. | Approved, Vet Approved |
| Heroin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Heroin. | Approved, Illicit |
| Hexamethonium | The risk or severity of adverse effects can be increased when Hexamethonium is combined with Sufentanil. | Experimental |
| Hexobarbital | The risk or severity of adverse effects can be increased when Sufentanil is combined with Hexobarbital. | Approved |
| Homatropine | The risk or severity of adverse effects can be increased when Homatropine is combined with Sufentanil. | Approved |
| Hydracarbazine | Sufentanil may increase the serotonergic activities of Hydracarbazine. | Experimental |
| Hydralazine | The risk or severity of adverse effects can be increased when Hydralazine is combined with Sufentanil. | Approved |
| Hydrochlorothiazide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Hydrochlorothiazide. | Approved, Vet Approved |
| Hydrocodone | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. | Approved, Illicit |
| Hydroflumethiazide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Hydroflumethiazide. | Approved |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil. | Approved, Illicit |
| Hydroxyamphetamine | Hydroxyamphetamine hydrobromide may increase the analgesic activities of Sufentanil. | Approved |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved |
| Hyoscyamine | The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Sufentanil. | Approved |
| Idelalisib | The serum concentration of Sufentanil can be increased when it is combined with Idelalisib. | Approved |
| Iloperidone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Iloperidone. | Approved |
| Iloprost | The risk or severity of adverse effects can be increased when Iloprost is combined with Sufentanil. | Approved, Investigational |
| Imatinib | The metabolism of Sufentanil can be decreased when combined with Imatinib. | Approved |
| Imidapril | The risk or severity of adverse effects can be increased when Imidapril is combined with Sufentanil. | Investigational |
| Imipramine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Imipramine. | Approved |
| Indalpine | Sufentanil may increase the serotonergic activities of Indalpine. | Investigational, Withdrawn |
| Indapamide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide. | Approved |
| Indenolol | Sufentanil may increase the bradycardic activities of Indenolol. | Withdrawn |
| Indinavir | The metabolism of Sufentanil can be decreased when combined with Indinavir. | Approved |
| Indoramin | The risk or severity of adverse effects can be increased when Indoramin is combined with Sufentanil. | Withdrawn |
| Ipratropium bromide | The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Sufentanil. | Approved |
| Iproclozide | Sufentanil may increase the serotonergic activities of Iproclozide. | Withdrawn |
| Iproniazid | Sufentanil may increase the serotonergic activities of Iproniazid. | Withdrawn |
| Irbesartan | The risk or severity of adverse effects can be increased when Irbesartan is combined with Sufentanil. | Approved, Investigational |
| Isavuconazonium | The metabolism of Sufentanil can be decreased when combined with Isavuconazonium. | Approved, Investigational |
| Isocarboxazid | Sufentanil may increase the serotonergic activities of Isocarboxazid. | Approved |
| Isoflurane | The risk or severity of adverse effects can be increased when Sufentanil is combined with Isoflurane. | Approved, Vet Approved |
| Isosorbide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide. | Approved |
| Isosorbide Dinitrate | The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Sufentanil. | Approved |
| Isosorbide Mononitrate | The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Sufentanil. | Approved |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Sufentanil. | Approved, Withdrawn |
| Isradipine | The metabolism of Sufentanil can be decreased when combined with Isradipine. | Approved |
| Itraconazole | The metabolism of Sufentanil can be decreased when combined with Itraconazole. | Approved, Investigational |
| Ivabradine | Sufentanil may increase the bradycardic activities of Ivabradine. | Approved |
| Ivacaftor | The serum concentration of Sufentanil can be increased when it is combined with Ivacaftor. | Approved |
| Ketamine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketamine. | Approved, Vet Approved |
| Ketazolam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketazolam. | Approved |
| Ketobemidone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketobemidone. | Approved |
| Ketoconazole | The metabolism of Sufentanil can be decreased when combined with Ketoconazole. | Approved, Investigational |
| Labetalol | Labetalol may increase the bradycardic activities of Sufentanil. | Approved |
| Lacidipine | The risk or severity of adverse effects can be increased when Lacidipine is combined with Sufentanil. | Approved |
| Lacosamide | Sufentanil may increase the atrioventricular blocking (AV block) activities of Lacosamide. | Approved |
| Lamotrigine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Lamotrigine. | Approved, Investigational |
| Landiolol | Sufentanil may increase the bradycardic activities of Aop200704. | Investigational |
| Lanreotide | Sufentanil may increase the bradycardic activities of Lanreotide. | Approved |
| Lercanidipine | The risk or severity of adverse effects can be increased when Lercanidipine is combined with Sufentanil. | Approved, Investigational |
| Levetiracetam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Levetiracetam. | Approved, Investigational |
| Levobunolol | Sufentanil may increase the bradycardic activities of Levobunolol. | Approved |
| Levobupivacaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Levobupivacaine. | Approved |
| Levocabastine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Levocabastine. | Approved |
| Levocetirizine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Levocetirizine. | Approved |
| Levodopa | Sufentanil may increase the orthostatic hypotensive activities of Levodopa. | Approved |
| Levomethadyl Acetate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Levomethadyl Acetate. | Approved |
| Levomilnacipran | Sufentanil may increase the serotonergic activities of Levomilnacipran. | Approved |
| Levorphanol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Levorphanol. | Approved |
| Levosimendan | The risk or severity of adverse effects can be increased when Levosimendan is combined with Sufentanil. | Approved, Investigational |
| Lidocaine | The risk or severity of adverse effects can be increased when Lidocaine is combined with Sufentanil. | Approved, Vet Approved |
| Lisdexamfetamine | Lisdexamfetamine may increase the analgesic activities of Sufentanil. | Approved, Investigational |
| Lisinopril | The risk or severity of adverse effects can be increased when Lisinopril is combined with Sufentanil. | Approved, Investigational |
| Lithium | The risk or severity of adverse effects can be increased when Sufentanil is combined with Lithium. | Approved |
| Lofentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Lofentanil. | Illicit |
| Lofexidine | The risk or severity of adverse effects can be increased when Lofexidine is combined with Sufentanil. | Approved, Investigational |
| Lopinavir | The metabolism of Sufentanil can be decreased when combined with Lopinavir. | Approved |
| Loratadine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Loratadine. | Approved |
| Lorazepam | The risk or severity of adverse effects can be increased when Lorazepam is combined with Sufentanil. | Approved |
| Losartan | The risk or severity of adverse effects can be increased when Losartan is combined with Sufentanil. | Approved |
| Lovastatin | The metabolism of Sufentanil can be decreased when combined with Lovastatin. | Approved, Investigational |
| Loxapine | The risk or severity of adverse effects can be increased when Loxapine is combined with Sufentanil. | Approved |
| Lucinactant | Sufentanil may increase the bradycardic activities of Lucinactant. | Approved |
| Luliconazole | The serum concentration of Sufentanil can be increased when it is combined with Luliconazole. | Approved |
| Lumacaftor | The metabolism of Sufentanil can be increased when combined with Lumacaftor. | Approved |
| Lurasidone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone. | Approved |
| Magnesium Sulfate | Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved, Vet Approved |
| Mannitol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Mannitol. | Approved, Investigational |
| Maprotiline | The risk or severity of adverse effects can be increased when Sufentanil is combined with Maprotiline. | Approved |
| Mebanazine | Sufentanil may increase the serotonergic activities of Mebanazine. | Withdrawn |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil. | Approved |
| Meclizine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Meclizine. | Approved |
| Medetomidine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Medetomidine. | Vet Approved |
| Melatonin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Melatonin. | Approved, Nutraceutical, Vet Approved |
| Melperone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Melperone. | Approved |
| Mephedrone | Mephedrone may increase the analgesic activities of Sufentanil. | Investigational |
| Mephentermine | Mephentermine may increase the analgesic activities of Sufentanil. | Approved |
| Mepivacaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Mepivacaine. | Approved, Vet Approved |
| Meprobamate | The risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil. | Approved, Illicit |
| Mersalyl | The risk or severity of adverse effects can be increased when Sufentanil is combined with Mersalyl. | Approved |
| Mesoridazine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Mesoridazine. | Approved |
| Metaxalone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Metaxalone. | Approved |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Sufentanil. | Approved |
| Methadyl Acetate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Methadyl Acetate. | Approved, Illicit |
| Methamphetamine | Methamphetamine may increase the analgesic activities of Sufentanil. | Approved, Illicit |
| Methantheline | The risk or severity of adverse effects can be increased when Methantheline is combined with Sufentanil. | Approved |
| Methapyrilene | The risk or severity of adverse effects can be increased when Sufentanil is combined with Methapyrilene. | Withdrawn |
| Methaqualone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Methaqualone. | Illicit, Withdrawn |
| Methazolamide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Methazolamide. | Approved |
| Methocarbamol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Methocarbamol. | Approved, Vet Approved |
| Methohexital | The risk or severity of adverse effects can be increased when Methohexital is combined with Sufentanil. | Approved |
| Methotrimeprazine | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. | Approved |
| Methoxyflurane | The risk or severity of adverse effects can be increased when Sufentanil is combined with Methoxyflurane. | Approved, Vet Approved |
| Methsuximide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide. | Approved |
| Methyclothiazide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Methyclothiazide. | Approved |
| Methyldopa | Sufentanil may increase the bradycardic activities of Methyldopa. | Approved |
| Methylecgonine | The risk or severity of adverse effects can be increased when Sufentanil is combined with ECGONINE METHYL ESTER. | Experimental |
| Methylene blue | Sufentanil may increase the serotonergic activities of Methylene blue. | Investigational |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Sufentanil is combined with Methylphenobarbital. | Approved |
| Metipranolol | Sufentanil may increase the bradycardic activities of Metipranolol. | Approved |
| Metixene | The risk or severity of adverse effects can be increased when Metixene is combined with Sufentanil. | Approved |
| Metolazone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone. | Approved |
| Metoprolol | Metoprolol may increase the bradycardic activities of Sufentanil. | Approved, Investigational |
| Metyrosine | Sufentanil may increase the sedative activities of Metyrosine. | Approved |
| Midazolam | The risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil. | Approved, Illicit |
| Mifepristone | The serum concentration of Sufentanil can be increased when it is combined with Mifepristone. | Approved, Investigational |
| Milnacipran | Sufentanil may increase the serotonergic activities of Milnacipran. | Approved |
| Minaprine | Sufentanil may increase the serotonergic activities of Minaprine. | Approved |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved, Investigational |
| Minoxidil | The risk or severity of adverse effects can be increased when Minoxidil is combined with Sufentanil. | Approved |
| Mirtazapine | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. | Approved |
| Mitotane | The serum concentration of Sufentanil can be decreased when it is combined with Mitotane. | Approved |
| MMDA | MMDA may increase the analgesic activities of Sufentanil. | Experimental, Illicit |
| Moclobemide | Sufentanil may increase the serotonergic activities of Moclobemide. | Approved |
| Modafinil | The serum concentration of Sufentanil can be decreased when it is combined with Modafinil. | Approved, Investigational |
| Moexipril | The risk or severity of adverse effects can be increased when Moexipril is combined with Sufentanil. | Approved |
| Molindone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Molindone. | Approved |
| Moricizine | Moricizine may increase the hypotensive activities of Sufentanil. | Approved, Withdrawn |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil. | Approved, Investigational |
| Moxonidine | The risk or severity of adverse effects can be increased when Moxonidine is combined with Sufentanil. | Approved |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved, Investigational |
| Nadolol | Sufentanil may increase the bradycardic activities of Nadolol. | Approved |
| Nafcillin | The serum concentration of Sufentanil can be decreased when it is combined with Nafcillin. | Approved |
| Nalbuphine | Nalbuphine may decrease the analgesic activities of Sufentanil. | Approved |
| Naltrexone | The therapeutic efficacy of Sufentanil can be decreased when used in combination with Naltrexone. | Approved, Investigational, Vet Approved |
| Nebivolol | Sufentanil may increase the bradycardic activities of Nebivolol. | Approved, Investigational |
| Nefazodone | The metabolism of Sufentanil can be decreased when combined with Nefazodone. | Approved, Withdrawn |
| Nelfinavir | The metabolism of Sufentanil can be decreased when combined with Nelfinavir. | Approved |
| Nesiritide | The risk or severity of adverse effects can be increased when Nesiritide is combined with Sufentanil. | Approved, Investigational |
| Netupitant | The serum concentration of Sufentanil can be increased when it is combined with Netupitant. | Approved |
| Nevirapine | The metabolism of Sufentanil can be increased when combined with Nevirapine. | Approved |
| Nialamide | Sufentanil may increase the serotonergic activities of Nialamide. | Withdrawn |
| Nicardipine | The risk or severity of adverse effects can be increased when Nicardipine is combined with Sufentanil. | Approved |
| Nicorandil | Nicorandil may increase the hypotensive activities of Sufentanil. | Approved |
| Nifedipine | The risk or severity of adverse effects can be increased when Nifedipine is combined with Sufentanil. | Approved |
| Nilotinib | The metabolism of Sufentanil can be decreased when combined with Nilotinib. | Approved, Investigational |
| Nilvadipine | The risk or severity of adverse effects can be increased when Nilvadipine is combined with Sufentanil. | Approved |
| Nimodipine | The risk or severity of adverse effects can be increased when Nimodipine is combined with Sufentanil. | Approved |
| Nisoldipine | The risk or severity of adverse effects can be increased when Nisoldipine is combined with Sufentanil. | Approved |
| Nitrazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrazepam. | Approved |
| Nitrendipine | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil. | Approved |
| Nitric Oxide | The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sufentanil. | Approved |
| Nitroglycerin | The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Sufentanil. | Approved, Investigational |
| Nitroprusside | The risk or severity of adverse effects can be increased when Nitroprusside is combined with Sufentanil. | Approved |
| Nitrous oxide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrous oxide. | Approved, Vet Approved |
| Norflurane | The risk or severity of adverse effects can be increased when Sufentanil is combined with 1,1,1,2 Tetrafluoroethane. | Investigational |
| Normethadone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Normethadone. | Approved, Illicit |
| Nortriptyline | The risk or severity of adverse effects can be increased when Sufentanil is combined with Nortriptyline. | Approved |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sufentanil. | Approved |
| Octamoxin | Sufentanil may increase the serotonergic activities of Octamoxin. | Withdrawn |
| Octreotide | Octreotide may increase the bradycardic activities of Sufentanil. | Approved, Investigational |
| Olanzapine | The risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil. | Approved, Investigational |
| Olaparib | The metabolism of Sufentanil can be decreased when combined with Olaparib. | Approved |
| Olmesartan | The risk or severity of adverse effects can be increased when Olmesartan is combined with Sufentanil. | Approved, Investigational |
| Olopatadine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Olopatadine. | Approved |
| Ondansetron | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ondansetron. | Approved |
| Opium | The risk or severity of adverse effects can be increased when Sufentanil is combined with Opium. | Approved, Illicit |
| Orphenadrine | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. | Approved |
| Osanetant | The risk or severity of adverse effects can be increased when Sufentanil is combined with Osanetant. | Investigational |
| Osimertinib | The serum concentration of Sufentanil can be increased when it is combined with Osimertinib. | Approved |
| Oxazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxazepam. | Approved |
| Oxethazaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxetacaine. | Investigational |
| Oxprenolol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxprenolol. | Approved |
| Oxybuprocaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxybuprocaine. | Approved |
| Oxybutynin | The risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil. | Approved, Investigational |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Sufentanil. | Approved, Illicit, Investigational |
| Oxymorphone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxymorphone. | Approved, Investigational, Vet Approved |
| Oxyphenonium | The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Sufentanil. | Approved |
| Paclitaxel | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Sufentanil. | Approved, Vet Approved |
| Palbociclib | The serum concentration of Sufentanil can be increased when it is combined with Palbociclib. | Approved |
| Paliperidone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Paliperidone. | Approved |
| Pancuronium | The risk or severity of adverse effects can be increased when Pancuronium is combined with Sufentanil. | Approved |
| Papaverine | The risk or severity of adverse effects can be increased when Papaverine is combined with Sufentanil. | Approved |
| Paraldehyde | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. | Approved |
| Pargyline | Sufentanil may increase the serotonergic activities of Pargyline. | Approved |
| Paroxetine | Sufentanil may increase the serotonergic activities of Paroxetine. | Approved, Investigational |
| Pasireotide | Sufentanil may increase the bradycardic activities of Pasireotide. | Approved |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil. | Approved |
| Penbutolol | Sufentanil may increase the bradycardic activities of Penbutolol. | Approved, Investigational |
| Pentazocine | Pentazocine may decrease the analgesic activities of Sufentanil. | Approved, Vet Approved |
| Pentobarbital | The metabolism of Sufentanil can be increased when combined with Pentobarbital. | Approved, Vet Approved |
| Pentolinium | The risk or severity of adverse effects can be increased when Pentolinium is combined with Sufentanil. | Approved |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved |
| Perazine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Perazine. | Investigational |
| Perindopril | The risk or severity of adverse effects can be increased when Perindopril is combined with Sufentanil. | Approved |
| Perospirone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Perospirone. | Approved |
| Perphenazine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Perphenazine. | Approved |
| Pethidine | The risk or severity of adverse effects can be increased when Pethidine is combined with Sufentanil. | Approved |
| Phenelzine | Sufentanil may increase the serotonergic activities of Phenelzine. | Approved |
| Pheniprazine | Sufentanil may increase the serotonergic activities of Pheniprazine. | Withdrawn |
| Phenobarbital | The metabolism of Sufentanil can be increased when combined with Phenobarbital. | Approved |
| Phenoxybenzamine | The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sufentanil. | Approved |
| Phenoxyethanol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenoxyethanol. | Approved |
| Phenoxypropazine | Sufentanil may increase the serotonergic activities of Phenoxypropazine. | Withdrawn |
| Phentermine | Phentermine may increase the analgesic activities of Sufentanil. | Approved, Illicit |
| Phentolamine | The risk or severity of adverse effects can be increased when Phentolamine is combined with Sufentanil. | Approved |
| Phenytoin | The metabolism of Sufentanil can be increased when combined with Phenytoin. | Approved, Vet Approved |
| Pimozide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Pimozide. | Approved |
| Pindolol | Sufentanil may increase the bradycardic activities of Pindolol. | Approved |
| Pipamperone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Pipamperone. | Approved |
| Pipecuronium | The risk or severity of adverse effects can be increased when Pipecuronium is combined with Sufentanil. | Approved |
| Pipotiazine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Pipotiazine. | Approved |
| Pirenzepine | The risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil. | Approved |
| Piretanide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Piretanide. | Experimental |
| Piritramide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Piritramide. | Investigational |
| Pirlindole | Sufentanil may increase the serotonergic activities of Pirlindole. | Approved |
| Pivhydrazine | Sufentanil may increase the serotonergic activities of Pivhydrazine. | Withdrawn |
| Pizotifen | The risk or severity of adverse effects can be increased when Sufentanil is combined with Pizotifen. | Approved |
| Polythiazide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Polythiazide. | Approved |
| Pomalidomide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide. | Approved |
| Poractant alfa | Sufentanil may increase the bradycardic activities of Poractant alfa. | Approved |
| Posaconazole | The metabolism of Sufentanil can be decreased when combined with Posaconazole. | Approved, Investigational, Vet Approved |
| Potassium | The risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium. | Approved |
| Potassium Citrate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium Citrate. | Approved, Vet Approved |
| Practolol | Sufentanil may increase the bradycardic activities of Practolol. | Approved |
| Pramipexole | Sufentanil may increase the sedative activities of Pramipexole. | Approved, Investigational |
| Pramocaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Pramocaine. | Approved |
| Prazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam. | Approved, Illicit |
| Prazosin | The risk or severity of adverse effects can be increased when Prazosin is combined with Sufentanil. | Approved |
| Pregabalin | The risk or severity of adverse effects can be increased when Pregabalin is combined with Sufentanil. | Approved, Illicit, Investigational |
| Prilocaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Prilocaine. | Approved |
| Primidone | The metabolism of Sufentanil can be increased when combined with Primidone. | Approved, Vet Approved |
| Procaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Procaine. | Approved, Investigational, Vet Approved |
| Prochlorperazine | The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sufentanil. | Approved, Vet Approved |
| Procyclidine | The risk or severity of adverse effects can be increased when Procyclidine is combined with Sufentanil. | Approved |
| Promazine | The risk or severity of adverse effects can be increased when Promazine is combined with Sufentanil. | Approved, Vet Approved |
| Promethazine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Promethazine. | Approved |
| Propafenone | Sufentanil may increase the bradycardic activities of Propafenone. | Approved |
| Propantheline | The risk or severity of adverse effects can be increased when Propantheline is combined with Sufentanil. | Approved |
| Proparacaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Proparacaine. | Approved, Vet Approved |
| Propiopromazine | Propiopromazine may increase the hypotensive activities of Sufentanil. | Vet Approved |
| Propiverine | The risk or severity of adverse effects can be increased when Propiverine is combined with Sufentanil. | Investigational |
| Propofol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Propofol. | Approved, Investigational, Vet Approved |
| Propoxycaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Propoxycaine. | Approved |
| Propranolol | Propranolol may increase the bradycardic activities of Sufentanil. | Approved, Investigational |
| Protriptyline | The risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline. | Approved |
| PSD502 | The risk or severity of adverse effects can be increased when Sufentanil is combined with PSD502. | Investigational |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Sufentanil. | Approved |
| Quazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Quazepam. | Approved, Illicit |
| Quetiapine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Quetiapine. | Approved |
| Quinapril | The risk or severity of adverse effects can be increased when Quinapril is combined with Sufentanil. | Approved, Investigational |
| Quinethazone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Quinethazone. | Approved |
| Quinidine | The risk or severity of adverse effects can be increased when Quinidine is combined with Sufentanil. | Approved |
| Raclopride | The risk or severity of adverse effects can be increased when Sufentanil is combined with Raclopride. | Investigational |
| Ramelteon | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ramelteon. | Approved, Investigational |
| Ramipril | The risk or severity of adverse effects can be increased when Ramipril is combined with Sufentanil. | Approved |
| Ramosetron | Sufentanil may increase the constipating activities of Ramosetron. | Approved |
| Ranolazine | The metabolism of Sufentanil can be decreased when combined with Ranolazine. | Approved, Investigational |
| Rasagiline | Sufentanil may increase the serotonergic activities of Rasagiline. | Approved |
| Remifentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Remifentanil. | Approved |
| Remoxipride | The risk or severity of adverse effects can be increased when Remoxipride is combined with Sufentanil. | Approved, Withdrawn |
| Reserpine | The risk or severity of adverse effects can be increased when Reserpine is combined with Sufentanil. | Approved |
| Rifabutin | The metabolism of Sufentanil can be increased when combined with Rifabutin. | Approved |
| Rifampicin | The metabolism of Sufentanil can be increased when combined with Rifampicin. | Approved |
| Rifapentine | The metabolism of Sufentanil can be increased when combined with Rifapentine. | Approved |
| Riociguat | The risk or severity of adverse effects can be increased when Riociguat is combined with Sufentanil. | Approved |
| Risperidone | Sufentanil may increase the hypotensive activities of Risperidone. | Approved, Investigational |
| Ritanserin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ritanserin. | Investigational |
| Ritobegron | Ritobegron may increase the analgesic activities of Sufentanil. | Investigational |
| Ritonavir | The metabolism of Sufentanil can be decreased when combined with Ritonavir. | Approved, Investigational |
| Rivastigmine | Sufentanil may increase the bradycardic activities of Rivastigmine. | Approved, Investigational |
| Rolofylline | The risk or severity of adverse effects can be increased when Sufentanil is combined with Rolofylline. | Investigational |
| Romifidine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Romifidine. | Vet Approved |
| Ropinirole | Sufentanil may increase the sedative activities of Ropinirole. | Approved, Investigational |
| Ropivacaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sufentanil. | Approved |
| Rotigotine | Sufentanil may increase the sedative activities of Rotigotine. | Approved |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Sufentanil. | Approved |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Sufentanil. | Approved |
| Sacubitril | The risk or severity of adverse effects can be increased when Sacubitril is combined with Sufentanil. | Approved |
| Safrazine | Sufentanil may increase the serotonergic activities of Safrazine. | Withdrawn |
| Saquinavir | The metabolism of Sufentanil can be decreased when combined with Saquinavir. | Approved, Investigational |
| Scopolamine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Scopolamine. | Approved |
| Scopolamine butylbromide | The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Sufentanil. | Approved, Vet Approved |
| Secobarbital | The risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil. | Approved, Vet Approved |
| Selegiline | Sufentanil may increase the serotonergic activities of Selegiline. | Approved, Investigational, Vet Approved |
| Sepranolone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Uc1010. | Investigational |
| Sertindole | The risk or severity of adverse effects can be increased when Sufentanil is combined with Sertindole. | Approved, Withdrawn |
| Sertraline | Sufentanil may increase the serotonergic activities of Sertraline. | Approved |
| Sevoflurane | The risk or severity of adverse effects can be increased when Sufentanil is combined with Sevoflurane. | Approved, Vet Approved |
| Sildenafil | The metabolism of Sufentanil can be decreased when combined with Sildenafil. | Approved, Investigational |
| Siltuximab | The serum concentration of Sufentanil can be decreased when it is combined with Siltuximab. | Approved |
| Simeprevir | The serum concentration of Sufentanil can be increased when it is combined with Simeprevir. | Approved |
| Sodium Nitrite | The risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Sufentanil. | Approved |
| Sodium oxybate | Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved |
| Solifenacin | The risk or severity of adverse effects can be increased when Solifenacin is combined with Sufentanil. | Approved |
| Sotalol | Sotalol may increase the bradycardic activities of Sufentanil. | Approved |
| Spironolactone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Spironolactone. | Approved |
| St. John's Wort | The serum concentration of Sufentanil can be decreased when it is combined with St. John's Wort. | Nutraceutical |
| Stiripentol | The serum concentration of Sufentanil can be increased when it is combined with Stiripentol. | Approved |
| Streptokinase | The risk or severity of adverse effects can be increased when Streptokinase is combined with Sufentanil. | Approved |
| Succinylcholine | Succinylcholine may increase the bradycardic activities of Sufentanil. | Approved |
| Sulfisoxazole | The metabolism of Sufentanil can be decreased when combined with Sulfisoxazole. | Approved, Vet Approved |
| Sulpiride | The risk or severity of adverse effects can be increased when Sulpiride is combined with Sufentanil. | Approved |
| Suvorexant | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. | Approved |
| Tamsulosin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tamsulosin. | Approved, Investigational |
| Tandospirone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tandospirone. | Investigational |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil. | Approved |
| Tasimelteon | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tasimelteon. | Approved |
| Telaprevir | The metabolism of Sufentanil can be decreased when combined with Telaprevir. | Withdrawn |
| Telithromycin | The metabolism of Sufentanil can be decreased when combined with Telithromycin. | Approved |
| Telmisartan | The risk or severity of adverse effects can be increased when Telmisartan is combined with Sufentanil. | Approved, Investigational |
| Temazepam | The risk or severity of adverse effects can be increased when Temazepam is combined with Sufentanil. | Approved |
| Terazosin | The risk or severity of adverse effects can be increased when Terazosin is combined with Sufentanil. | Approved |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrabenazine. | Approved |
| Tetracaine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetracaine. | Approved, Vet Approved |
| Tetrodotoxin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrodotoxin. | Investigational |
| Thalidomide | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. | Approved, Investigational, Withdrawn |
| Theobromine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Theobromine. | Approved |
| Thiamylal | The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiamylal. | Approved, Vet Approved |
| Thiethylperazine | Thiethylperazine may increase the hypotensive activities of Sufentanil. | Withdrawn |
| Thiopental | The risk or severity of adverse effects can be increased when Thiopental is combined with Sufentanil. | Approved, Vet Approved |
| Thioridazine | The risk or severity of adverse effects can be increased when Thioridazine is combined with Sufentanil. | Withdrawn |
| Thiothixene | The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene. | Approved |
| Tiagabine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiagabine. | Approved |
| Tiapride | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiapride. | Approved, Investigational |
| Ticlopidine | The metabolism of Sufentanil can be decreased when combined with Ticlopidine. | Approved |
| Ticrynafen | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ticrynafen. | Withdrawn |
| Tiletamine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiletamine. | Vet Approved |
| Timolol | Timolol may increase the bradycardic activities of Sufentanil. | Approved |
| Tiotropium | The risk or severity of adverse effects can be increased when Tiotropium is combined with Sufentanil. | Approved |
| Tizanidine | Tizanidine may increase the bradycardic activities of Sufentanil. | Approved |
| Tocilizumab | The serum concentration of Sufentanil can be decreased when it is combined with Tocilizumab. | Approved |
| Tofacitinib | Tofacitinib may increase the bradycardic activities of Sufentanil. | Approved, Investigational |
| Tolazoline | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tolazoline. | Approved, Vet Approved |
| Tolcapone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tolcapone. | Approved, Withdrawn |
| Toloxatone | Sufentanil may increase the serotonergic activities of Toloxatone. | Approved |
| Tolterodine | The risk or severity of adverse effects can be increased when Tolterodine is combined with Sufentanil. | Approved, Investigational |
| Tolvaptan | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tolvaptan. | Approved |
| Topiramate | The risk or severity of adverse effects can be increased when Sufentanil is combined with Topiramate. | Approved |
| Torasemide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide. | Approved |
| Tramadol | The risk or severity of adverse effects can be increased when Tramadol is combined with Sufentanil. | Approved, Investigational |
| Trandolapril | The risk or severity of adverse effects can be increased when Trandolapril is combined with Sufentanil. | Approved |
| Trans-2-Phenylcyclopropylamine | Sufentanil may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine. | Experimental |
| Tranylcypromine | Sufentanil may increase the serotonergic activities of Tranylcypromine. | Approved |
| Trazodone | The risk or severity of adverse effects can be increased when Trazodone is combined with Sufentanil. | Approved, Investigational |
| Tretinoin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Tretinoin. | Approved, Investigational, Nutraceutical |
| Triamterene | The risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene. | Approved |
| Triazolam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Triazolam. | Approved |
| Trichlormethiazide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Trichlormethiazide. | Approved, Vet Approved |
| Trifluoperazine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluoperazine. | Approved |
| Triflupromazine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Sufentanil. | Approved, Vet Approved |
| Trihexyphenidyl | The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Sufentanil. | Approved |
| Trimethaphan | The risk or severity of adverse effects can be increased when Trimethaphan is combined with Sufentanil. | Approved |
| Trimipramine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Trimipramine. | Approved |
| Triprolidine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Triprolidine. | Approved |
| Tropicamide | The risk or severity of adverse effects can be increased when Tropicamide is combined with Sufentanil. | Approved |
| Trospium | The risk or severity of adverse effects can be increased when Trospium is combined with Sufentanil. | Approved |
| Tubocurarine | The risk or severity of adverse effects can be increased when Tubocurarine is combined with Sufentanil. | Approved |
| Ularitide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ularitide. | Investigational |
| Umeclidinium | The risk or severity of adverse effects can be increased when Umeclidinium is combined with Sufentanil. | Approved |
| Valproic Acid | The risk or severity of adverse effects can be increased when Valproic Acid is combined with Sufentanil. | Approved, Investigational |
| Valsartan | The risk or severity of adverse effects can be increased when Valsartan is combined with Sufentanil. | Approved, Investigational |
| Vecuronium | The risk or severity of adverse effects can be increased when Vecuronium is combined with Sufentanil. | Approved |
| Venlafaxine | The metabolism of Sufentanil can be decreased when combined with Venlafaxine. | Approved |
| Verapamil | The metabolism of Sufentanil can be decreased when combined with Verapamil. | Approved |
| Vigabatrin | The risk or severity of adverse effects can be increased when Sufentanil is combined with Vigabatrin. | Approved |
| Voriconazole | The metabolism of Sufentanil can be decreased when combined with Voriconazole. | Approved, Investigational |
| Vortioxetine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Vortioxetine. | Approved |
| Xylazine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Xylazine. | Vet Approved |
| Zaleplon | The risk or severity of adverse effects can be increased when Sufentanil is combined with Zaleplon. | Approved, Illicit, Investigational |
| Ziconotide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ziconotide. | Approved |
| Zimelidine | Sufentanil may increase the serotonergic activities of Zimelidine. | Withdrawn |
| Ziprasidone | The metabolism of Sufentanil can be decreased when combined with Ziprasidone. | Approved |
| Zolazepam | The risk or severity of adverse effects can be increased when Sufentanil is combined with Zolazepam. | Vet Approved |
| Zolpidem | Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. | Approved |
| Zonisamide | The risk or severity of adverse effects can be increased when Sufentanil is combined with Zonisamide. | Approved, Investigational |
| Zopiclone | The risk or severity of adverse effects can be increased when Sufentanil is combined with Zopiclone. | Approved |
| Zotepine | The risk or severity of adverse effects can be increased when Sufentanil is combined with Zotepine. | Approved |
| Zuclopenthixol | The risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol. | Approved, Investigational |
